skip to Main Content

New Data Analytics Approaches for Novel Curative Therapies & APMs

  • This page as PDF


Avalere experts discussed new data analytics and health economics and outcomes research approaches for evaluating key value-based topics in healthcare, including novel curative therapy affordability and access, alternative payment models, and the increasingly important role of real-world evidence in healthcare decision-making.

The rise of novel curative therapy development has led to critical advanced treatment options for patients with hard-to-treat diseases, while also forcing a paradigm shift in defining value and enabling access and affordability. The growth of alternative payment models has the potential to expand access to these treatments. Now more than ever, real-world evidence and new data analytics and health economics approaches are vital to inform strategies for product access and payment in the evolving healthcare landscape, in the midst of the COVID-19 pandemic, and going forward.

Key topics included:

  • Health economics approaches to defining value of novel therapies and other interventions
  • Novel therapy affordability and access considerations
  • Value-based alternative payment models
  • Real-world evidence in healthcare decision-making
  • COVID-19 impacts today and going forward


Christie Teigland , Principal, Health Economics & Advanced Analytics

Christie Teigland, PhD, leads the design and implementation of studies focused on comparative effectiveness, predictive analytics, and performance measure development and testing.

John Feore , Associate Principal, Center for Healthcare Transformation

John Feore advises healthcare providers, plans, and life sciences companies on the transformation of the healthcare system.

Brian Leinwand , Associate Principal, Health Economics & Advanced Analytics

Brian Leinwand provides strategic health economics support throughout a product’s life-cycle and helps clients build evidence packages that demonstrate and support the value of their products.

John C. Neal , Managing Director, Commercialization & Regulatory Strategy

John C. Neal partners with pharmaceutical and biotech clients to develop market access assessments and launch strategies designed to ensure successful commercialization of assets.

From beginning to end, our team synergy
produces measurable results. Let's work together.

Sign up to receive more insights about Real-World Data
Please enter your email address to be notified when new Real-World Data insights are published.

Back To Top